(Reuters) – Europe’s leading association of oncologists has thrown its weight behind cheaper copycat versions of biotech cancer drugs that have lost patent protection, saying they are effective and affordable.
(Reuters) – Europe’s leading association of oncologists has thrown its weight behind cheaper copycat versions of biotech cancer drugs that have lost patent protection, saying they are effective and affordable.